I

n a victory for the pharmaceutical industry, the U.S. Supreme Court limited the right for people from anywhere in the country to file product-liability lawsuits against drug makers in California and several other states where courts are seen as more hospitable to consumers.

The ruling came in response to a debate over jurisdiction, which can be used to determine where a lawsuit may be filed. Last year, the California Supreme Court clarified the extent to which Bristol-Myers Squibb needed to have a presence in California in order to be sued by hundreds of people from Texas, Ohio, and 33 other states, who claim they were harmed by its Plavix blood thinner.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy